ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 249 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | -18.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $249 | -24.1% | 37,100 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $328 | +15.9% | 37,100 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $283 | -99.8% | 37,100 | +71.8% | 0.00% | +100.0% |
| Q3 2022 | $154,000 | -12.0% | 21,600 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $175,000 | -41.7% | 21,600 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $300,000 | -50.5% | 21,600 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $606,000 | -17.4% | 21,600 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $734,000 | -16.9% | 21,600 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $883,000 | +2.9% | 21,600 | +1.4% | 0.01% | 0.0% |
| Q1 2021 | $858,000 | -16.6% | 21,300 | +22.4% | 0.01% | -16.7% |
| Q4 2020 | $1,029,000 | +21.6% | 17,400 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $846,000 | -55.4% | 17,400 | -55.6% | 0.01% | -25.0% |
| Q2 2020 | $1,896,000 | – | 39,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |